Seasonal influenza virus vaccine H1N1 intranasal - Altimmune

Drug Profile

Seasonal influenza virus vaccine H1N1 intranasal - Altimmune

Alternative Names: NasoVAX™ Seasonal Influenza Vaccine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vaxin
  • Developer Altimmune
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention) in USA (Intranasal, Spray)
  • 08 Oct 2015 Altimmune plans a phase II trial for Influenza-A virus subtype H1N1 in USA
  • 01 Sep 2015 Vaxin is now called Altimmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top